News | January 29, 2022
DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
It has also been granted permission to conduct trials for booster dose
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
Goal of providing 12-month internship opportunities for qualified students
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
Floods had forced the plans in Mahad to shut down
This is the first of its kind vaccine for Covid 19 to get the go-ahead
The company is confident of commencing production at both Mahad and Chiplun units soon
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
Subscribe To Our Newsletter & Stay Updated
